We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AUSTEDO (Teva Pharma Australia Pty Ltd)
Product name
AUSTEDO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
190 (255 working days)
Active ingredients
deutetrabenazine
Registration type
NCE/NBE
Indication
AUSTEDO (modified release tablet) is indicated for the treatment of:
- chorea associated with Huntington's disease
- tardive dyskinesia in adults